WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jerome Charles BressiChief Regulatory and Quality Officer2025-01-105,980$1.55
$9.27kSell
Bahram ValamehrPresident and CEO2025-01-108,705$1.54
$13.41kSell
Cindy TahlChief Legal Compliance Officer and Secretary2025-01-105,654$1.55
$8.76kSell
Redmile Group LLCDirector2024-12-20397,964$1.68
$668.58kBuy
Redmile Group LLCDirector2024-12-20341,633$1.68
$573.94kSell
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MSell
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MBuy
Yuan XuDirector2024-08-06633$4.23
$2.68kSell
Edward J. Dulac IiiChief Financial Officer2024-03-042,447$7.77
$19.01kSell

1 of 1

FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC22.58%25,712,223$36.51MInsider
Blackrock Inc9.61%10,941,582$15.54MInstitution
Vanguard Group Inc9.07%10,333,033$14.67MInstitution
Amir Nashat8.65%9,852,967$13.99MInsider
Polaris Venture Management Co V LLC8.64%9,841,933$13.98MInsider
Ecor1 Capital LLC2.68%3,049,405$4.33MInstitution
Ovp Venture Partners VII LP2.63%2,998,112$4.26MInsider
Dimensional Fund Advisors LP2.54%2,898,377$4.12MInstitution
Goldman Sachs Group Inc2.17%2,476,414$3.52MInstitution
Arch Venture Fund VI LP2.17%2,473,188$3.51MInsider

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE47.56%51.88%Net BuyingNet Buying
CKPT11.56%25.06%Net SellingNet Selling
THRD54.77%45.23%Net Selling
SLDB23.93%76.07%Net SellingNet Selling
GLSI7.53%92.47%Net BuyingNet Buying
View Top Biotech Stocks

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 47.56% institutional shareholders, 51.88% Fate Therapeutics insiders, and 0.56% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 25.71M shares representing 22.58% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $36.51M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.